Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027

MT Newswires Live

09/10

Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.

Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.

Price: 4.32, Change: -0.03, Percent Change: -0.69

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2666594628"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2666594628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2666594628?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 22:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2666594628","market":"hk","top_or_hot":-1,"title":"Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027","media":"MT Newswires Live","content":"<html><body><p> Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.</p><p>Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.</p><p>Price: 4.32, Change: -0.03, Percent Change: -0.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Optimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOptimi Health to Start Phase 2 Trial of Psilocybin-Assisted Therapy for Major Depressive Disorder in H1 2027\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-09-10 22:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.</p><p>Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.</p><p>Price: 4.32, Change: -0.03, Percent Change: -0.69</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2666594628","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2666594628","pubTimestamp":1789052267,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Optimi Health  plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.Price: 4.32, Change: -0.03, Percent Change: -0.69","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","OPTH":"OPTIMI HEALTH CORP."},"translate_title":"Optimi Health 将于 2027 年上半年启动裸盖菇素辅助治疗重度抑郁症的 2 期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPTH":1},"content_text":"Optimi Health (OPTH) plans to start a phase 2 clinical trial to evaluate psilocybin-assisted therapy in individuals with major depressive disorder in H1 2027, the company said Thursday.Health Canada has approved the trial, which targets to enroll up to 200 participants across several sites in Canada, according to the statement. The trial's primary endpoint is the change in Montgomery-Asberg Depression Rating Scale total score from baseline, Optimi Health said.Price: 4.32, Change: -0.03, Percent Change: -0.69","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}